Azithromycin or montelukast as inhaled corticosteroid–sparing agents in moderate-to-severe childhood asthma study
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background Clinical trials in children with moderate to severe persistent asthma are limited. Objective To determine if azithromycin or montelukast are inhaled corticosteroid-sparing. Methods The budesonide dose [with salmeterol (50 mcg) twice daily] necessary to achieve control was determined in children 6–17 years of age with moderate to severe persistent asthma. After a budesonide-stable period of 6 weeks, children were randomized in a double-masked, parallel, multi-center study to receive once nightly azithromycin, montelukast, or matching placebos, plus the established controlling dose of budesonide (minimum 400 mcg BID) and salmeterol twice daily. Primary outcome was time from randomization to inadequate asthma control following sequential budesonide dose reduction. Results Of 292 children screened, only 55 were randomized. Inadequate adherence to study medication (n=80) and improved asthma control under close medical supervision (n=49) were the major reasons for randomization failure. A futility analysis was requested by the Data Safety Monitoring Board. In data available for analyses, no differences were noted for either treatment compared to placebo in time to inadequate control status (median, weeks (95% CL) azithromycin: 8.4 (4.3, 17.3), montelukast 13.9 (4.7, 20.6), placebo 19.1 (11.7, infinity)), with no difference between the groups (logrank test, p = 0.49). The futility analysis indicated that even if the planned sample size was reached, results of this negative study were unlikely to be different and the trial was prematurely terminated. Conclusion Based upon these results, neither azithromycin nor montelukast is likely to be an effective ICS-sparing alternative in children with moderate to severe persistent asthma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saiman, L., Marshall, B. C., Mayer-Hamblett, N., Burns, J. L., Quittner, A. L., Cibene, D. A., Coquillette, S., Fieberg, A. Y., Accurso, F. J., Campbell III, P. W., et al. (2003) · JAMA · doi:10.1001/jama.290.13.1749 · Cited by 958 · cited 1×
“When asthma control criteria were met by the increased dose of ICS, a patient was randomized to one of the three treatment arms, (1) placebo (one placebo montelukast tablet and one or two placebo azithromycin capsules) once daily, (2) azithromycin 250 mg (for those 25–40 kg) or 500 mg (for those >40 kg) once daily (11…”
Method
Cited by
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
“Two studies included children [300, 306] and two included adults [301, 305].”
BackgroundInfluentialMechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications
Kanoh, S., & Rubin, B. K. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00078-09 · Cited by 708
Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline
Holguin, F., Cardet, J. C., Chung, K. F., Diver, S., Ferreira, D. S., Fitzpatrick, A., Gaga, M., Kellermeyer, L., Khurana, S., Knight, S., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00588-2019 · Cited by 629
Teach, S. J., Gill, M. A., Togias, A., Sorkness, C. A., Arbes, S. J., Calatroni, A., Wildfire, J. J., Gergen, P. J., Cohen, R. T., Pongracic, J. A., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.09.008 · Cited by 537
Self-citationAsthma exacerbations: Origin, effect, and prevention
Jackson, D. J., Sykes, A., Mallia, P., & Johnston, S. L. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.10.024 · Cited by 343
Asthma outcomes: Exacerbations
Fuhlbrigge, A., Peden, D., Apter, A. J., Boushey, H. A., Camargo, C. A., Gern, J., Heymann, P. W., Martinez, F. D., Mauger, D., Teague, W. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.12.983 · Cited by 326
Self-citationChauhan, B. F., & Ducharme, F. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002314.pub3 · Cited by 306
Management of severe asthma in children
Bush, A., & Saglani, S. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61054-9 · Cited by 220
Guilbert, T. W., Bacharier, L. B., & Fitzpatrick, A. M. (2014) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2014.06.022 · Cited by 216
Self-citation
Metadata
- Authors
- Strunk, R. C., Bacharier, L. B., Phillips, B. R., Szefler, S. J., Zeiger, R. S., Chinchilli, V. M., Martinez, F. D., Lemanske, R. F., Taussig, L. M., Mauger, D. T., Morgan, W. J., Sorkness, C. A., Paul, I. M., Guilbert, T., Krawiec, M., Covar, R., & Larsen, G.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2008-12
- Volume
- 122
- Issue
- 6
- Pages
- 1138-1144.e4
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2037466531
- Cited by
- 134
- References
- 1
- FWCI
- 8.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.